Alphatec Holdings, Inc. (ATEC) Earnings
Alphatec Holdings, Inc. is expected to report next earnings on July 30, 2026 (in NaN days), with a consensus EPS estimate of $0.09. ATEC has beaten EPS estimates in 3 of its last 12 reported quarters (average surprise -429.2% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $-0.01 | $-0.22 | -2100.0% | $192M | -2.7% |
| Feb 24, 2026 | $0.04 | $0.06 | +50.0% | $213M | +5.3% |
| Oct 30, 2025 | $-0.03 | $0.03 | +200.0% | $197M | -6.1% |
| Jul 31, 2025 | $-0.06 | $0.02 | +133.3% | $186M | +1.6% |
| May 1, 2025 | $-0.12 | $-0.23 | -91.7% | $169M | -5.4% |
| Feb 26, 2025 | $-0.19 | $-0.23 | -21.1% | $177M | +2.3% |
| Oct 30, 2024 | $-0.27 | $-0.28 | -3.7% | $151M | -11.5% |
| Jul 31, 2024 | $-0.26 | $-0.29 | -11.5% | $146M | -1.1% |
| Feb 27, 2024 | $-0.28 | $-0.37 | -32.1% | $138M | +5.3% |
| Aug 3, 2023 | $-0.30 | $-0.43 | -43.3% | $117M | +6.4% |
| May 4, 2023 | $-0.32 | $-0.40 | -25.0% | $109M | +4.2% |
| Feb 28, 2023 | $-0.30 | $-0.33 | -10.0% | $106M | +3.7% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 5, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
• Business is scaling. Surgical revenue up 17%, cases up 21%, surgeons up 23%. EOS Insight evolving into a platform with growth and adoption creating momentum. • Invested in what's working, leaning into the durable growth model. • Strategy focuses on clinical distinction, surgeon adoption, and a strong sales engine. EOS has enabled access to prestigious institutions and is driving case volume and data generation. Valence is fitting into surgical workflow with positive feedback.
Guidance
• Expect total revenue for full year 2026 of approximately $882 million, 15% growth year over year. Surgical revenue approximately $805 million, unchanged from prior guidance, 17% growth. • Expect EOS revenue of approximately $77 million. • Expect adjusted EBITDA of approximately $134 million, 15% margin. • Expect at least $20 million in free cash flow for the full year, second quarter free cash flow expected to approximate zero.
Segment performance
Total revenue was $192 million, up 14% year-over-year. Surgical revenue was $178 million, growing 17%. Cases up 21%, surgeons up 23%. EOS revenue was $14 million for the quarter. Generated $21 million of EBITDA. Total revenue contribution: Surgical was 92.7% ($178M / $192M), EOS was 7.3% ($14M / $192M).
Risks & headwinds
• EOS revenue fell short of quarterly goal due to execution issues in sales, downstream marketing, and support. • Seasonality and weather impacts can affect revenue. • Deceleration in revenue in Q1 with recovery in April but still some unpredictability in recent quarters related to execution flaws in EOS installations.
Analyst Q&A
Q: Regarding 2027 LRP revenue number and consensus,
A: Adjustment to EOS guidance reflects near-term execution issues addressed by adding sales and marketing resources, believing on track to long-range plan.
Q: On pricing per case headwind,
A: Revenue per case decline due to mix of cervical procedures, international business, and biologics attachment rate, expecting flat revenue per procedure for balance of year.
Q: On surgical Q1 performance and sequential,
A: Momentum in distinguishing procedures robust, surge in surgeon additions, April rebounded, confidence in full year plan.
Q: On EOS franchise cadence,
A: Expect EOS to contribute more meaningfully in second half, overall growth in second quarter similar to first quarter.
Q: On EOS execution weakness and impact,
A: EOS execution flaw, not bleeding into other parts of business.
Q: On surgical outlook confidence,
A: Confidence from demand profile of distinguishing procedures and surgeon adoption.
Q: On Valence placements and pull-through,
A: Valence doing as expected, utilized in PTP, trending toward more than target.
Q: On surgeon penetration and volume growth,
A: Strong surge in adoption, utilization rates growing, confidence in full year surgical guide from surgeon demand and procedural adoption.
Q: On EOS thesis,
A: EOS thesis intact, structured data set unique, committed to the strategy